Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Japan Panel Recognizes 6 More Deaths Possibly Linked to COVID Vaccines
November 8, 2022
- MOF Proposes Transition to Normal Framework for COVID Vaccines, Therapeutics
November 8, 2022
- MOF Renews Its Push for Full Drug Price Revision in FY2023
November 8, 2022
- Lower House Health Committee OKs Revised Bill to Amend Infectious Disease Act
November 7, 2022
- CEFP Will Thoroughly Discuss Drug Pricing and Discovery: Minister
November 4, 2022
- Moderna’s BA.4/5 COVID Booster Nabs Special Approval in Japan
November 1, 2022
- Label Expansion for TS-1, Enhertu and More in Line for November Approval
November 1, 2022
- MHLW Panel Puts Pfizer’s Precedex on Hold for Pediatric Indication
October 31, 2022
- Deloitte Proposes Pricing Schemes to Encourage Consolidation of Generic Makers
October 31, 2022
- Aricept’s Lewy Body Dementia Indication to Be Modified after Post-Launch Trial Miss
October 31, 2022
- MHLW Panel OKs 100 More Health Damage Claims for COVID-19 Vaccines
October 31, 2022
- Japan Adopts Stimulus Package, Set to Support Domestic API Production
October 31, 2022
- Think Tanks Propose New Pricing Methods for Innovative Meds, Multi-Faceted Evaluations
October 28, 2022
- Policy Veterans’ Group Advocates Drug Reimbursement at Actual Purchase Prices
October 28, 2022
- Ex-Bureaucrats, Academics Trade Barbs over Macroeconomic Indexing; Will MOF Allow Rise in Drug Cost?
October 28, 2022
- Chuikyo to Discuss 2023 Off-Year Re-Pricing with Its Implementation as Premise: MHLW
October 27, 2022
- LDP to Launch Lawmakers’ League on Medical Adhesive Patches
October 27, 2022
- Bill to Amend Infectious Disease Act and Other Laws Enter Diet Deliberations
October 26, 2022
- Pfizer Assesses Cancer Risk from Amoxan as “Acceptable” at “1 in 200,000 People”
October 26, 2022
- New Economic Package to Drive Antibiotic API Production, Vaccine Trials in Japan
October 25, 2022
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…